Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis

English version České info

Background:
Chronic kidney disease (CKD) is a frequent, under-recognized condition and a risk factor for renal failure and cardiovascular disease. Increasing evidence connects non-alcoholic fatty liver disease (NAFLD) to CKD. We conducted a meta-analysis to determine whether the presence and severity of NAFLD are associated with the presence and severity of CKD.

Methods and Findings:
English and non-English articles from international online databases from 1980 through January 31, 2014 were searched. Observational studies assessing NAFLD by histology, imaging, or biochemistry and defining CKD as either estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m² or proteinuria were included. Two reviewers extracted studies independently and in duplicate. Individual participant data (IPD) were solicited from all selected studies. Studies providing IPD were combined with studies providing only aggregate data with the two-stage method. Main outcomes were pooled using random-effects models. Sensitivity and subgroup analyses were used to explore sources of heterogeneity and the effect of potential confounders. The influences of age, whole-body/abdominal obesity, homeostasis model of insulin resistance (HOMA-IR), and duration of follow-up on effect estimates were assessed by meta-regression. Thirty-three studies (63,902 participants, 16 population-based and 17 hospital-based, 20 cross-sectional, and 13 longitudinal) were included. For 20 studies (61% of included studies, 11 cross-sectional and nine longitudinal, 29,282 participants), we obtained IPD. NAFLD was associated with an increased risk of prevalent (odds ratio [OR] 2.12, 95% CI 1.69–2.66) and incident (hazard ratio [HR] 1.79, 95% CI 1.65–1.95) CKD. Non-alcoholic steatohepatitis (NASH) was associated with a higher prevalence (OR 2.53, 95% CI 1.58–4.05) and incidence (HR 2.12, 95% CI 1.42–3.17) of CKD than simple steatosis. Advanced fibrosis was associated with a higher prevalence (OR 5.20, 95% CI 3.14–8.61) and incidence (HR 3.29, 95% CI 2.30–4.71) of CKD than non-advanced fibrosis. In all analyses, the magnitude and direction of effects remained unaffected by diabetes status, after adjustment for other risk factors, and in other subgroup and meta-regression analyses. In cross-sectional and longitudinal studies, the severity of NAFLD was positively associated with CKD stages. Limitations of analysis are the relatively small size of studies utilizing liver histology and the suboptimal sensitivity of ultrasound and biochemistry for NAFLD detection in population-based studies.

Conclusion:
The presence and severity of NAFLD are associated with an increased risk and severity of CKD.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis. PLoS Med 11(7): e32767. doi:10.1371/journal.pmed.1001680
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001680

Souhrn

Conclusion:
The presence and severity of NAFLD are associated with an increased risk and severity of CKD.

Please see later in the article for the Editors' Summary

Zdroje

1. McCulloughK, SharmaP, AliT, KhanI, SmithWC, et al. (2012) Measuring the population burden of chronic kidney disease: a systematic literature review of the estimated prevalence of impaired kidney function. Nephrol Dial Transplant 27: 1812–1821.

2. StevensPE, LevinA (2013) A Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members (2013) Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158: 825–830.

3. ThomasG, SehgalAR, KashyapSR, SrinivasTR, KirwanJP, et al. (2011) Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 6: 2364–2373.

4. JamesMT, HemmelgarnBR, TonelliM (2010) Early recognition and prevention of chronic kidney disease. Lancet 375: 1296–1309.

5. HerzogCA, AsingerRW, BergerAK, CharytanDM, DıezJ, et al. (2011) Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 80: 572–586.

6. BlackC, SharmaP, ScotlandG, McCulloughK, McGurnD, et al. (2010) Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis. Health Technol Assess 14: 1–184.

7. CoreshJ, Byrd-HoltD, AstorBC, BriggsJP, EggersPW, et al. (2005) Chronic kidney disease awareness, prevalence, and trends among US adults, 1999 to 2000. J Am Soc Nephrol 16: 180–188.

8. ChalasaniN, YounossiZ, LavineJE, DiehlAM, BruntEM, CusiK, et al. (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55: 2005–2023.

9. MussoG, GambinoR, CassaderM, PaganoGF (2011) Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 43: 617–649.

10. IxJH, SharmaK (2010) Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol 21: 406–412.

11. LeveyAS, CoreshJ, GreeneT, StevensLA, ZhangYL, et al. (2006) Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the Modification of Diet in Renal Disease study equation for estimating glomerular filtration rate. Ann Intern Med 145: 247–254.

12. LeveyAS, StevensLA, SchmidCH, ZhangYL, CastroAF3rd, et al. (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604–612.

13. StevensLA, CoreshJ, SchmidCH, FeldmanHI, FroissartM, et al. (2008) Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 51: 395–406.

14. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions (version 5.1.0) Available: http://www.cochrane.org/training/cochrane-handbook. Accessed 31 March 2013.

15. LiberatiA, AltmanDG, TetzlaffJ, MulrowC, GøtzschePC, et al. (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. J Clin Epidemiol 62: 1006–1012.

16. von ElmE, AltmanDG, EggerM, PocockSJ, GøtzschePC, et al. (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 147: 573–577.

17. HernaezR, LazoM, BonekampS (2011) Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 54: 1082–1090.

18. RileyRD, SimmondsMC, LookMP (2007) Evidence synthesis combining individual patient data and aggregate data: a systematic review identified current practice and possible methods. J Clin Epidemiol 60: 431–439.

19. RileyRD, SteyerbergEW (2010) Meta-analysis of a binary outcome using individual participant data and aggregate data. Research Syn Meth 1: 2–19.

20. HigginsJP, ThompsonSG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539–1558.

21. BögerCA, HeidIM (2011) Chronic kidney disease: novel insights from genome-wide association studies. Kidney Blood Press Res 34: 225–234.

22. ChangJM, HwangSJ, TsukamotoY, ChenHC (2012) Chronic kidney disease prevention–a challenge for Asian countries: report of the Third Asian Forum of Chronic Kidney Disease Initiatives. Clin Exp Nephrol 16: 187–194.

23. KirylukK, LiY, Sanna-CherchiS, RohanizadeganM, SuzukiH, et al. (2012) Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet 8: e1002765.

24. FarrellGC, WongVW, ChitturiS (2013) NAFLD in Asian–as common and important as in the West. Nat Rev Gastroenterol Hepatol 10: 307–318.

25. KwakernaakAJ, ZelleDM, BakkerSJ, NavisG (2013) Central body fat distribution associates with unfavorable renal hemodynamics independent of body mass index. J Am Soc Nephrol 24: 987–994.

26. DuvalS, TweedieR (2000) Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56: 455–463.

27. CamposGM, BambhaK, VittinghoffE, RablC, PosseltAM, et al. (2008) A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology 47: 1916–1923.

28. YilmazY, AlahdabYO, YonalO, KurtR, KedrahAE, et al. (2010) Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis. Metabolism 59: 1327–1330.

29. TargherG, BertoliniL, RodellaS, LippiG, ZoppiniG, et al. (2010) Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol 5: 2166–2171.

30. ParkCW, TsaiNT, WongLL (2011) Implications of worse renal dysfunction and medical comorbidities in patients with NASH undergoing liver transplant evaluation: impact on MELD and more. Clin Transplant 25: E606–E611.

31. YasuiK, SumidaY, MoriY, MitsuyoshiH, MinamiM, et al. (2011) Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. Metabolism 60: 735–739.

32. MussoG, CassaderM, De MichieliF, RosinaF, OrlandiF, et al. (2012) Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein. Metabolism Hepatology 56: 933–942.

33. FrancqueSM, VerrijkenA, MertensI, HubensG, Van MarckE, et al. (2012) Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients. Clin Gastroenterol Hepatol 10: 1162–1168.

34. MachadoMV, GonçalvesS, CarepaF, CoutinhoJ, CostaA, et al. (2012) Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease. Liver Int 32: 241–248.

35. KimYS, JungES, HurW, BaeSH, ChoiJY, et al. (2013) Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease. Clin Mol Hepatol 19: 120–130.

36. TargherG, BertoliniL, RodellaS, ZoppiniG, LippiG, et al. (2008) Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia 51: 444–450.

37. CasoinicF, SâmpeleanD, BădăuC, PrunăL (2009) Nonalcoholic fatty liver disease–a risk factor for microalbuminuria in type 2 diabetic patients. Rom J Intern Med 47: 55–59.

38. HwangST, ChoYK, YunJW, ParkJH, KimHJ, et al. (2010) Impact of non-alcoholic fatty liver disease on microalbuminuria in patients with prediabetes and diabetes. Intern Med J 40: 437–442.

39. TargherG, PichiriI, ZoppiniG, TrombettaM, BonoraE (2012) Increased prevalence of chronic kidney disease in patients with Type 1 diabetes and non-alcoholic fatty liver. Diabet Med 29: 220–226.

40. SirotaJC, McFannK, TargherG, ChoncholM, JalalDI (2012) Association between nonalcoholic liver disease and chronic kidney disease: an ultrasound analysis from NHANES 1988–1994. Am J Nephrol 36: 466–471.

41. LiG, ShiW, HugH, ChenY, LiuL, et al. (2012) Nonalcoholic fatty liver disease associated with impairment of kidney function in nondiabetes population. Biochem Med (Zagreb) 22: 92–99.

42. ArmstrongMJ, HoulihanDD, BenthamL, ShawJC, CrambR, et al. (2012) Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol 56: 234–240.

43. XiaMF, LinHD, LiXM, YanHM, BianH, et al. (2012) Renal function-dependent association of serum uric acid with metabolic syndrome and hepatic fat content in a middle-aged and elderly Chinese population. Clin Exp Pharmacol Physiol 39: 930–937.

44. AhnAL, ChoiJK, KimMN, KimSA, OhEJ, et al. (2013) Non-alcoholic fatty liver disease and chronic kidney disease in Koreans aged 50 years or older. Korean J Fam Med 34: 199–205.

45. AnjaneyaV, SirishaY, Pradeep BabuKV (2013) Can Non-alcoholic fatty liver disease (NAFLD) as a marker for microalbuminuria in prediabetes group? Iosr Journal of Pharmacy 3: 48–51.

46. TargherG, KendrickJ, SmitsG, ChoncholM (2010) Relationship between serum gamma-glutamyltransferase and chronic kidney disease in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001–2006. Nutr Metab Cardiovasc Dis 20: 583–590.

47. AdamsLA, LympJF, St SauverJ, SandersonSO, LindorKD, et al. (2005) The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129: 113–121.

48. EkstedtM, FranzénLE, MathiesenUL, ThoreliusL, HolmqvistM, et al. (2006) Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44: 865–873.

49. SöderbergC, StålP, AsklingJ, GlaumannH, LindbergG, et al. (2010) Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 51: 595–602.

50. WongVW, WongGL, ChoiPC, ChanAW, LiMK, et al. (2010) Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 59: 969–974.

51. AnguloP, BugianesiE, BjornssonES, CharatcharoenwitthayaP, MillsPR, et al. (2013) Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 145: 782–789.

52. HamaguchiM, KojimaT, TakedaN, NagataC, TakedaJ, et al. (2007) Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 13: 1579–1584.

53. ChangY, RyuS, SungE, WooHY, OhE, et al. (2008) Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism 57: 569–576.

54. TargherG, ChoncholM, BertoliniL, RodellaS, ZenariL, et al. (2008) Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol 19: 1564–1570.

55. LauK, LorbeerR, HaringR, SchmidtCO, WallaschofskiH, et al. (2010) The association between fatty liver disease and blood pressure in a population-based prospective longitudinal study. J Hypertens 28: 1829–1835.

56. AthyrosVG, TziomalosK, GossiosTD, GrivaT, AnagnostisP, et al. (2010) Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 376: 1916–1922.

57. El AzeemHA, Khalekel-SA, El-AkabawyH, NaeimH, KhalikHA, et al. (2013) Association between nonalcoholic fatty liver disease and the incidence of cardiovascular and renal events. J Saudi Heart Assoc 25: 239–246.

58. LeeDH, JacobsDRJr, GrossM, SteffesM (2005) Serum gamma-glutamyltransferase was differently associated with microalbuminuria by status of hypertension or diabetes: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem 51: 1185–1191.

59. RyuS, ChangY, KimDI, KimWS, SuhBS (2007) Gamma-glutamyltransferase as a predictor of chronic kidney disease in nonhypertensive and nondiabetic Korean men. Clin Chem 53: 71–77.

60. GilbertsonDT, LiuJ, XueJL, LouisTA, SolidCA, et al. (2005) Projecting the number of patients with endstage renal disease in the United States to the year 2015. J Am Soc Nephrol 16: 3736–3741.

61. AgopianVG, KaldasFM, HongJC, WhittakerM, HoltC, et al. (2012) Liver transplantation for nonalcoholic steatohepatitis: the new epidemic. Ann Surg 256: 624–633.

62. Scientific Registry of Transplant Recipients. Available: http://www.ustransplant.org/. Accessed 30 September 2013.

63. TargherG (2011) NAFLD and adverse hepatic and extra-hepatic outcomes. BMJ 343 Available: www.bmj.com/rapid-response/2011/12/05.

64. AnguloP (2011) Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 343 Available: http://www.bmj.com/rapid-response/2011/12/12.

65. AnsteeQM A Flawed Study and an Opportunity Missed. BMJ 2011: 343 at: http://www.bmj.com/rapid-response/2011/11/30.

66. QaseemA, HopkinsRHJr, SweetDE, StarkeyM, ShekelleP (2013) Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: a clinical practice guideline from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med 159: 835–847.

67. ZeinCO, UnalpA, ColvinR, LiuYC, McCulloughAJ (2011) Nonalcoholic Steatohepatitis Clinical Research Network. Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol 54: 753–759.

68. TsochatzisEA, PapatheodoridisGV (2010) Smoking is associated with histological severity in nonalcoholic steatohepatitis. Hepatology 52: 1522–1523.

69. HirataT, TomitaK, KawaiT, YokoyamaH, ShimadaA, et al. (2013) Effect of telmisartan or losartan for treatment of nonalcoholic fatty liver disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY). Int J Endocrinol 13: 587140.

70. FogariR, MaffioliP, MugelliniA, ZoppiA, LazzariP, et al. (2012) Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis. Eur J Gastroenterol Hepatol 24: 164–171.

71. HanKH, RhaSW, KangHJ, BaeJW, ChoiBJ, et al. (2012) Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage). J Clin Lipidol 6: 340–351.

72. MussoG, CassaderM, RosinaF, GambinoR (2012) Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 55: 885–904.

73. PerkinsRM, AboudaraMC, UyAL, OlsonSM, CushnerHM, et al. (2009) Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis 53: 606–616.

74. NakamuraT, FujiwaraN, KawagoeY, SugayaT, UedaY, et al. (2010) Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease. Eur J Clin Invest 40: 790–796.

75. NakamuraT, SatoE, FujiwaraN, KawagoeY, TakeuchiM, et al. (2010) Atorvastatin reduces proteinuria in non-diabetic chronic kidney disease patients partly via lowering serum levels of advanced glycation end products (AGEs). Oxid Med Cell Longev 3: 304–307.

76. MillerER3rd, JuraschekSP, AndersonCA, GuallarE, Henoch-RyugoK, et al. (2013) The effects of n-3 long-chain polyunsaturated fatty acid supplementation on biomarkers of kidney injury in adults with diabetes: results of the GO-FISH trial. Diabetes Care 36: 1462–1469.

77. GyebiL, SoltaniZ (2012) Reisin Lipid nephrotoxicity: new concept for an old disease. Curr Hypertens Rep 14: 177–181.

78. RüsterC, WolfG (2013) The role of the renin-angiotensin-aldosterone system in obesity-related renal diseases. Semin Nephrol 33: 44–53.

79. KalaitzidisRG, SiamopoulosKC (2011) The role of obesity in kidney disease: recent findings and potential mechanisms. Int Urol Nephrol 43: 771–784.

80. YilmazY (2010) The AGEs-RAGE axis and nonalcoholic steatohepatitis: the evidence mounts. J Gastroenterol 45: 782–783.

81. LiY, LiuL, WangB, WangJ, ChenD (2013) Simple steatosis is a more relevant source of serum inflammatory markers than omental adipose tissue. Clin Res Hepatol Gastroenterol 38: 46–54.

82. DogruT, GencH, TapanS, AslanF, ErcinCN, et al. (2013) Plasma fetuin-A is associated with endothelial dysfunction and subclinical atherosclerosis in subjects with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 78: 712–717.

83. LiY, SunX, YuY (2013) Serum fetuin-A levels related with microalbuminuria in diet-induced obese rats. Biomed Res Int 795103.

84. CrastoC, SembaRD, SunK, FerrucciL (2012) Serum fibroblast growth factor 21 is associated with renal function and chronic kidney disease in community-dwelling adults. J Am Geriatr Soc 60: 792–793.

85. MałgorzewiczS, Skrzypczak-JankunE, JankunJ (2013) Plasminogen activator inhibitor-1 in kidney pathology. Int J Mol Med 31: 503–510.

86. AdielsM, TaskinenMR, PackardC, CaslakeMJ, Soro-PaavonenA, et al. (2006) Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 49: 755–765.

87. DeFilippisAP, BlahaMJ, MartinSS, ReedRM, JonesSR, et al. (2013) Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 227: 429–436.

88. ZhaoHL, SuiY, HeL, GuanJ, XiaoSJ, et al. (2011) Lipid partitioning after uninephrectomy. Acta Diabetol 48: 317–328.

89. JinK, NorrisK, VaziriND (2013) Dysregulation of hepatic fatty acid metabolism in chronic kidney disease. Nephrol Dial Transplant 28: 313–320.

90. AhmedI, SuttonAJ, RileyRD (2012) Assessment of publication bias, selection bias, and unavailable data in meta-analyses using individual participant data: a database survey. BMJ 344: d7762.